Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +207.46%
#3 ONFA ONFA +54.25%
#4 Metaplex Metaplex +23.40%
#5 Osaka Protocol Osaka Protocol +21.54%
#6 Wrapped Krown Wrapped Krown +20.00%
#7 Talus Network Talus Network +19.98%
#8 DODO DODO +17.78%
#9 Black Phoenix Black Phoenix +15.09%
#10 Magma Finance Magma Finance +14.74%
Coin of the day
DeFiChain DeFiChain
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Clasificación en acciones #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Precio por acción
$0.94180721
Capitalización bursátil
$22.26M
Cambio (1 día)
0.38%
Cambio (1 año)
-14.35%
País
FR
Comercio Valbiotis SA (ALVAL)

Categoría

Healthcare
Ganancias de Valbiotis SA (ALVAL)
Ganancias en Dec 2025 TTM: $-11.05M
Secondo gli ultimi rapporti finanziari di Valbiotis SA, gli utili attuali della società sono $-11.05M. Nel 2023, la società ha registrato un utile di $-10.39M, un aumento con respecto a agli utili del 2022, che erano di $-15.24M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Valbiotis SA desde 2015 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-11.05M 6.26%
2024 $-10.40M 0.09%
2023 $-10.39M -31.83%
2022 $-15.24M 28.45%
2021 $-11.86M 91.50%
2020 $-6.19M -17.90%
2019 $-7.54M 32.17%
2018 $-5.71M 94.72%
2017 $-2.93M 369.81%
2016 $-623.95K -40.51%
2015 $-1.05M 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$24.72B -223,839.46%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -46,859.02%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -46,779.37%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -19,450.04%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.48B -13,505.47%
NL